Loading…
Reported covered position: Sr. Counsel, House Energy & Commerce
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price.
Client: SPECIALTY & BIOTECH DISTRIBUTORS ASSOCATION · Firm: SIDLEY AUSTIN LLP
Implementation of Average Sales Price (ASP) Methodology; exclusion of prompt pay discounts from ASP; H.R. 1392
To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
GRIFOLS INC via SIDLEY AUSTIN LLP
2009 · third_quarter · 3A
Issues related to biological reimbursements being considered in health care reform legislation and to Medicare, Medicaid and Health Care reform, including Medicaid rebates, IVIG access and 340B expansion, H.R. 3200 and S. 1679 (Americas Affordable Health Choices Act of 2009), and Americas Healthy Future Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA via SIDLEY AUSTIN LLP
2009 · third_quarter · 3A
Source: Senate LDA
Client: SPECIALTY & BIOTECH DISTRIBUTORS ASSOCATION · Firm: SIDLEY AUSTIN LLP
Implementation of Average Sales Price (ASP) Methodology; exclusion of prompt pay discounts from ASP; H.R. 1392
To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price.
Client: SPECIALTY & BIOTECH DISTRIBUTORS ASSOCATION · Firm: SIDLEY AUSTIN LLP
Implementation of Average Sales Price (ASP) Methodology; exclusion of prompt pay discounts from ASP; H.R. 1392
America's Affordable Health Choices Act of 2009
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA · Firm: SIDLEY AUSTIN LLP
Health care reform, H.R. 3200
America's Affordable Health Choices Act of 2009
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA · Firm: SIDLEY AUSTIN LLP
Health care reform, H.R. 3200
America's Affordable Health Choices Act of 2009
Client: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA · Firm: SIDLEY AUSTIN LLP
Health care reform, H.R. 3200
America's Affordable Health Choices Act of 2009
Client: GRIFOLS INC · Firm: SIDLEY AUSTIN LLP
Issues related to biological reimbursements being considered in health care reform legislation and to Medicare, Medicaid and Health Care reform, including Medicaid rebates, IVIG access and 340B expansion, H.R. 3200 and S. 1679 (Americas Affordable Health Choices Act of 2009), and Americas Healthy Future Act.
America's Affordable Health Choices Act of 2009
Client: GRIFOLS INC · Firm: SIDLEY AUSTIN LLP
Issues related to biological reimbursements being considered in health care reform legislation and to Medicare, Medicaid and Health Care reform, including Medicaid rebates, IVIG access and 340B expansion, H.R. 3200 and S. 1679 (Americas Affordable Health Choices Act of 2009), and Americas Healthy Future Act.
Oil Spill Accountability and Environmental Protection Act of 2010
Client: GENENTECH · Firm: SIDLEY AUSTIN LLP
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Oil Spill Accountability and Environmental Protection Act of 2010
Client: GENENTECH · Firm: SIDLEY AUSTIN LLP
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Oil Spill Accountability and Environmental Protection Act of 2010
Client: GENENTECH · Firm: SIDLEY AUSTIN LLP
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Oil Spill Accountability and Environmental Protection Act of 2010
Client: GENENTECH · Firm: SIDLEY AUSTIN LLP
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Oil Spill Accountability and Environmental Protection Act of 2010
Client: GENENTECH · Firm: SIDLEY AUSTIN LLP
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways to Biosimilars Act)
Oil Spill Accountability and Environmental Protection Act of 2010
Client: GENENTECH · Firm: SIDLEY AUSTIN LLP
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues related to biological reimbursements being considered in health care reform legislation and to Medicare, Medicaid and Health Care reform, including Medicaid rebates, IVIG access and 340B expansion, H.R. 3200 and S. 1679 (Americas Affordable Health Choices Act of 2009), and Americas Healthy Future Act.
Issues related to biological reimbursements being considered in health care reform legislation and to Medicare, Medicaid and Health Care reform, including Medicaid rebates, IVIG access and 340B expansion, H.R. 3200 and S. 1679 (Americas Affordable Health Choices Act of 2009), and Americas Healthy Future Act.
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways to Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways to Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways to Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price.
Client: SPECIALTY & BIOTECH DISTRIBUTORS ASSOCATION · Firm: SIDLEY AUSTIN LLP
Implementation of Average Sales Price (ASP) Methodology and Competitive Acquisition Program; Implementation of AMP; exclusion of prompt pay discounts from ASP; H.R.2770
To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price.
Client: SPECIALTY & BIOTECH DISTRIBUTORS ASSOCATION · Firm: SIDLEY AUSTIN LLP
Implementation of Average Sales Price (ASP) Methodology and Competitive Acquisition Program; Implementation of AMP; exclusion of prompt pay discounts from ASP; H.R.2770
Health care reform, H.R. 3200
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
GENENTECH via SIDLEY AUSTIN LLP
2009 · third_quarter · 3A
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
GENENTECH via SIDLEY AUSTIN LLP
2009 · third_quarter · Q3
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA via SIDLEY AUSTIN LLP
2009 · third_quarter · Q3
Health care reform, H.R. 3200
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
GENENTECH via SIDLEY AUSTIN LLP
2009 · third_quarter · Q3
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
GENENTECH via SIDLEY AUSTIN LLP
2009 · third_quarter · Q3
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
GRIFOLS INC via SIDLEY AUSTIN LLP
2009 · third_quarter · Q3
Issues related to biological reimbursements being considered in health care reform legislation and to Medicare, Medicaid and Health Care reform, including Medicaid rebates, IVIG access and 340B expansion, H.R. 3200 and S. 1679 (Americas Affordable Health Choices Act of 2009), and Americas Healthy Future Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SUNOVION PHARMACEUTICALS INC via SIDLEY AUSTIN LLP
2009 · third_quarter · Q3
Medicare reimbursement issues; opposition to use of price referencing; health care reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SPECIALTY & BIOTECH DISTRIBUTORS ASSOCATION via SIDLEY AUSTIN LLP
2009 · third_quarter · Q3
Implementation of Average Sales Price (ASP) Methodology; exclusion of prompt pay discounts from ASP; H.R. 1392
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA via SIDLEY AUSTIN LLP
2009 · third_quarter · Q3
Health care reform, H.R. 3200
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
SPECIALTY & BIOTECH DISTRIBUTORS ASSOCATION via SIDLEY AUSTIN LLP
2009 · second_quarter · Q2
Implementation of Average Sales Price (ASP) Methodology; exclusion of prompt pay discounts from ASP; H.R. 1392
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SUNOVION PHARMACEUTICALS INC via SIDLEY AUSTIN LLP
2009 · second_quarter · Q2
Medicare reimbursement issues; opposition to use of price referencing
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via SIDLEY AUSTIN LLP
2009 · second_quarter · Q2
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
GRIFOLS INC via SIDLEY AUSTIN LLP
2009 · second_quarter · Q2
Reimbursement issues relating to Medicare, Medicaid and Health Care reform, including Medicaid rebates, IVIG access and 340B expansion.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SUNOVION PHARMACEUTICALS INC via SIDLEY AUSTIN LLP
2009 · first_quarter · Q1
Medicare reimbursement issues; opposition to use of price referencing
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASSISTIVE TECHNOLOGY GROUP via SIDLEY AUSTIN LLP
2009 · first_quarter · 1T
Medicare annual payment update
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SPECIALTY & BIOTECH DISTRIBUTORS ASSOCATION via SIDLEY AUSTIN LLP
2009 · first_quarter · Q1
Implementation of Average Sales Price (ASP) Methodology; exclusion of prompt pay discounts from ASP; H.R. 1392
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS INC via SIDLEY AUSTIN LLP
2009 · first_quarter · Q1
Reimbursement issues relating to Medicare; including IVIG access bills
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via SIDLEY AUSTIN LLP
2009 · first_quarter · Q1
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways to Biosimilars Act)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
GRIFOLS INC via SIDLEY AUSTIN LLP
2008 · fourth_quarter · Q4
Reimbursement issues relating to Medicare; including IVIG access bills
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SUNOVION PHARMACEUTICALS INC via SIDLEY AUSTIN LLP
2008 · fourth_quarter · Q4
Medicare reimbursement issues; opposition to use of price referencing
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SPECIALTY & BIOTECH DISTRIBUTORS ASSOCATION via SIDLEY AUSTIN LLP
2008 · fourth_quarter · Q4
Implementation of Average Sales Price (ASP) Methodology and Competitive Acquisition Program; Implementation of AMP; exclusion of prompt pay discounts from ASP; H.R.2770
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASSISTIVE TECHNOLOGY GROUP via SIDLEY AUSTIN LLP
2008 · fourth_quarter · Q4
Contract issues related to competitive bidding implementation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SUNOVION PHARMACEUTICALS INC via SIDLEY AUSTIN LLP
2008 · third_quarter · Q3
Medicare reimbursement issues; opposition to use of price referencing
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SPECIALTY & BIOTECH DISTRIBUTORS ASSOCATION via SIDLEY AUSTIN LLP
2008 · third_quarter · Q3
Implementation of Average Sales Price (ASP) Methodology and Competitive Acquisition Program; Implementation of AMP; exclusion of prompt pay discounts from ASP; H.R.2770
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASSISTIVE TECHNOLOGY GROUP via SIDLEY AUSTIN LLP
2008 · third_quarter · Q3
Contract issues related to competitive bidding implementation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GRIFOLS INC via SIDLEY AUSTIN LLP
2008 · third_quarter · Q3
Reimbursement issues relating to Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SUNOVION PHARMACEUTICALS INC via SIDLEY AUSTIN LLP
2008 · second_quarter · Q2
Medicare reimbursement issues; opposition to use of price referencing
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SPECIALTY & BIOTECH DISTRIBUTORS ASSOCATION via SIDLEY AUSTIN LLP
2008 · second_quarter · Q2
Implementation of Average Sales Price (ASP) Methodology and Competitive Acquisition Program; Implementation of AMP; exclusion of prompt pay discounts from ASP
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASSISTIVE TECHNOLOGY GROUP via SIDLEY AUSTIN LLP
2008 · second_quarter · Q2
Contract issues related to competitive bidding implementation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE